Molecular epidemiology of methicillin-resistant Staphylococcus aureus from bacteraemia in northern Italy

Infez Med. 2012 Dec;20(4):256-64.

Abstract

Background: Vancomycin is frequently used in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia; reduced susceptibility to vancomycin is therefore disturbing.

Methods: molecular epidemiological analysis of 81 MRSA bacteraemia isolates collected during 2002-10 in the province of Bolzano, northern Italy was performed. MICs of a range of antimicrobials were determined by agar microdilution, screening for hGISA was by Macro-Etest and Etest GRD and confirmed by PAP-AUC with vancomycin and teicoplanin. All isolates were characterised by toxin gene profiling, agr, spa, and SCCmec-typing; MLST and PFGE were carried out on representative strains.

Results: The dominant clones identified were ST8-MRSA-IVc (55%) and ST228- and ST111-MRSA-I (25%); most of the latter two lineages (19/20; 95%) were GISA or PAP-AUC confirmed hGISA. One ST8-MRSA-IVc isolate harboured ccrA2B2 together with ccrA4B4. The remainder were diverse genotypically and belonged to MLST clonal complexes 1, 22, 45 and 398.

Conclusions: Diverse lineages of MRSA were identified as causing bacteraemia in a province in northern Italy. The association of a specific genotype with the hGISA and GISA phenotypes among representatives of the second most common lineage identified is of clinical concern.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bacteremia / microbiology*
  • Female
  • Humans
  • Italy
  • Male
  • Methicillin-Resistant Staphylococcus aureus* / drug effects
  • Methicillin-Resistant Staphylococcus aureus* / genetics
  • Microbial Sensitivity Tests
  • Middle Aged
  • Molecular Epidemiology
  • Retrospective Studies
  • Staphylococcal Infections / epidemiology*
  • Staphylococcal Infections / microbiology*
  • Teicoplanin / pharmacology
  • Vancomycin / pharmacology
  • Vancomycin Resistance

Substances

  • Teicoplanin
  • Vancomycin